BioArctic’s partner Eisai receives China NMPA approval for Leqembi IV maintenance dosing to treat early Alzheimer’s disease: Stockholm Tuesday, September 30, 2025, 12:00 Hrs [ ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback